[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608537":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":35,"responsibleParty":52,"collaborators":10,"id":55,"slug":10,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":21,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Neoadjuvant Chemotherapy + mpMRI Group",null,"Patients with clinical stage cT2-T4 muscle-invasive bladder cancer receiving standard gemcitabine\u002Fcisplatin neoadjuvant chemotherapy. Each patient undergoes three multiparametric MRI scans: at baseline (pre-NAC), 24 hours after the first cisplatin dose, and post-NAC before cystectomy. Imaging biomarkers (K\\^trans\\^, Ve, ADC index) are analyzed and correlated with pathological response after radical cystectomy.",[13],"Diagnostic Test: Multiparametric Magnetic Resonance Imaging (mpMRI)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Multiparametric Magnetic Resonance Imaging (mpMRI)","Multiparametric MRI (mpMRI) performed at three defined timepoints: prior to neoadjuvant chemotherapy (baseline), 24 hours after first cisplatin dose in the first NAC cycle, and after completing NAC but before radical cystectomy. Imaging protocols include T2-weighted imaging, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Quantitative imaging biomarkers such as K\\^trans\\^, Ve, and ADC index are extracted and analyzed to evaluate early treatment response and predict pathological outcomes following chemotherapy.",[9],[21],"mpMRI",[23],{"name":24,"affiliation":25,"role":26},"Amr Darwish, Lecturer","Urology Department, Faculty of Medicine, Assiut University, Assiut, Egypt","PRINCIPAL_INVESTIGATOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Hamza mohamed, MBBCh","CONTACT","+201101336409","Hamza.Ahmed00099@med.aun.edu.eg",{"name":24,"role":30,"phone":10,"phoneExt":10,"email":34},"amrdarwish@aun.edu.eg",[36],{"facility":37,"status":38,"city":39,"state":10,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Amr E. Darwish","RECRUITING","Asyut","Egypt","EG",{"type":43,"coordinates":44},"Point",[45,46],31.18368,27.18096,{"lat":46,"lon":45},[49],{"name":50,"role":30,"phone":51,"phoneExt":10,"email":34},"Urology Department, Faculty of Medicine, Assiut University Dr, MD","+201015817851",{"type":26,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Amr Esam Saad Mohamed Darwish","Lecturer","100608537",false,"NCT07202845","Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI","Inclusion Criteria:\n\n* Patients diagnosed with cT2-T4 urothelial carcinoma of the urinary bladder, according to the TNM classification (8), who give informed, written consent on participation in the study and approve all its requirements.\n* Planned to receive cisplatin-based NAC followed by radical cystectomy.\n* Willing to undergo three mpMRI scans (baseline, 24h post-initial cisplatin, and post-NAC).\n\nExclusion Criteria:\n\n* Patients who have received pelvic radiotherapy.\n* Severe renal impairment\n* Previous open or laparoscopic pelvic surgery.\n* Presence of distant metastases at diagnosis.\n* Patients with contraindications to MRI.\n* Ineligibility to cisplatin","ALL","18 Years",{"count":63,"type":64},39,"ESTIMATED","OBSERVATIONAL","Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.",[68,21,69],"MIBC","NAC",[71],"ultiparametric MRI, mpMRI, Diffusion-Weighted Imaging, DWI","2025-09-24",{"date":74,"type":75},"2025-10-02","ACTUAL",{"date":77,"type":75},"2025-08-29",{"date":79,"type":64},"2026-06-01",{"name":5,"class":6},1]